On the way to Crohn's disease and ulcerative colitis control: fatigue as part of a novel composite endpoint (ECCO 2022)

Gastro-enterologie

15/03 - Ambitious therapeutic goals in the therapy of inflammatory bowel disease need more stringent individual endpoints. Several definitions for composite endpoints are under evaluation to describe disease control. Most commonly symptomatic (PRO2) remission is combined with endoscopic response, histology and/or biomarker remission. Here this analysis explores the addition of fatigues as a lead problem reported by patients with IBD as part of a composite endpoint in an analysis of a prospective open label observation trial.